| Title |
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition
|
|---|---|
| Published in |
Drugs, November 2018
|
| DOI | 10.1007/s40265-018-1009-0 |
| Pubmed ID | |
| Authors |
Brian K. Chen, Y. Tony Yang, Charles L. Bennett |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 80% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 40% |
| Members of the public | 2 | 40% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 21% |
| Researcher | 10 | 13% |
| Student > Bachelor | 9 | 11% |
| Student > Doctoral Student | 5 | 6% |
| Other | 4 | 5% |
| Other | 10 | 13% |
| Unknown | 25 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 15% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Immunology and Microbiology | 2 | 3% |
| Economics, Econometrics and Finance | 2 | 3% |
| Other | 11 | 14% |
| Unknown | 28 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2023.
All research outputs
#1,037,028
of 25,837,817 outputs
Outputs from Drugs
#81
of 3,500 outputs
Outputs of similar age
#20,422
of 339,683 outputs
Outputs of similar age from Drugs
#2
of 30 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,500 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,683 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.